BCHE
Cholinesterase
As of the edition of 20 October 2026, BCHE (cholinesterase, UniProt P06276) has 4 drugs tested at it and 9 companies on the list, 0 on route A and 3 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P06276
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Secreted
- Solved structures
- 113
- Disease areas
- Nervous system; Mental health; Heart and blood vessels; Injuries; Chemically induced; Inherited and neonatal; Immune system
- Registered trials of its drugs
- 69
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Withdrawn from market | 1 |
| Status not established | 1 |
| Total | 4 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Rivastigmine | Marketed | Phase 4 | none listed |
| IVL3003 | Status not established | Phase 2 | none listed |
| Tacrine | Marketed | Phase 2 | none listed |
| Propanidid | Withdrawn from market | No phase stated | none listed |
4 of 4 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 3 |
| Undetermined | 6 |
| Total on the list | 9 |
| Company | Route |
|---|---|
| Novartis | Route B |
| Ono Pharmaceutical | Route B |
| Shionogi | Route B |
The other 6 companies at BCHE
In the product9 companies in all; 6 are not named here, and no score is.
See the 9 companies at BCHE, ranked, with the facts behind eachRequest access. Nothing is shown until you do.